Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
362-06-015 ISMRM Abstract

CSF flow dynamics throughout the ventricular system in preclinical Alzheimer’s disease using 4D flow MRI

Primary: Neuro - Alzheimer's Disease
Secondary: Neuro - Neurofluids
362-06-015 · Neuroimaging Biomarkers of Aging, Vascular Health, and Dementia · Monday, 11 May, 5:05 PM–6:00 PM · Digital Posters Row C
Keywords: Alzheimer's Disease 4D flow MRI Cerebrospinal fluid flow
Accepted
Tomas Vikner 1,2, Kevin M Johnson1,3, Rachael E Wilson4, Tobey J Betthauser4, Victoria Williams4, Henrik Zetterberg5, Sanjay Asthana4, Sterling C Johnson4, Leonardo Rivera-Rivera1,4
1Department of Medical Physics, University of Wisconsin - Madison, Madison, United States of America
2Department of Diagnostics and Intervention, Biomedical Engineering and Radiation Physics, Umeå University, Umeå, Sweden
3Department of Radiology, University of Wisconsin - Madison, Madison, United States of America
4Department of Medicine, University of Wisconsin - Madison, Madison, United States of America
5Department of Pathology and Laboratory Medicine, University of Wisconsin - Madison, Madison, United States of America
Presenting Author: Tomas Vikner

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216. doi:10.1016/S1474-4422(12)70291-0 [doi]
2. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330(6012):1774. doi:10.1126/science.1197623 [doi]
3. Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012;4(147):147ra111-147ra111. doi:10.1126/scitranslmed.3003748 [doi]
4. Bohr T, Hjorth PG, Holst SC, et al. The glymphatic system: Current understanding and modeling. iScience. 2022;25(9):104987. doi:10.1016/j.isci.2022.104987 [doi]
5. Wen Q, Tong Y, Zhou X, Dzemidzic M, Ho CY, Wu YC. Assessing pulsatile waveforms of paravascular cerebrospinal fluid dynamics within the glymphatic pathways using dynamic diffusion-weighted imaging (dDWI). NeuroImage. 2022;260:119464. doi:10.1016/j.neuroimage.2022.119464 [doi]
6. Han F, Lee J, Chen X, et al. Global brain activity and its coupling with cerebrospinal fluid flow is related to tau pathology. Alzheimers Dement J Alzheimers Assoc. 2024;20(12):8541-8555. doi:10.1002/alz.14296 [doi]
7. Rivera-Rivera LA, Vikner T, Eisenmenger L, Johnson SC, Johnson KM. Four-dimensional flow MRI for quantitative assessment of cerebrospinal fluid dynamics: Status and opportunities. NMR Biomed. 2024;37(7):e5082. doi:10.1002/nbm.5082 [doi]
8. Vikner T, Johnson KM, Cadman RV, et al. CSF dynamics throughout the ventricular system using 4D flow MRI: associations to arterial pulsatility, ventricular volumes, and age. Fluids Barriers CNS. 2024;21(1):68. doi:10.1186/s12987-024-00570-4 [doi]
9. Johnson SC, Koscik RL, Jonaitis EM, et al. The Wisconsin Registry for Alzheimer’s Prevention: A review of findings and current directions. Alzheimers Dement Diagn Assess Dis Monit. 2017;10:130-142. doi:10.1016/j.dadm.2017.11.007 [doi]
10. Loecher M, Schrauben E, Johnson KM, Wieben O. Phase unwrapping in 4D MR flow with a 4D single-step laplacian algorithm. J Magn Reson Imaging JMRI. 2016;43(4):833-842. doi:10.1002/jmri.25045 [doi]
11. Jonaitis EM, Janelidze S, Cody KA, et al. Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease. Brain Commun. 2023;5(2):fcad057. doi:10.1093/braincomms/fcad057 [doi]
12. Cody KA, Langhough RE, Zammit MD, et al. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer’s disease. Brain J Neurol. 2024;147(6):2144-2157. doi:10.1093/brain/awae116 [doi]
13. Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. 2024;81(3):255-263. doi:10.1001/jamaneurol.2023.5319 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/362-06-015